Hikal Limited has rescheduled its earnings conference call to discuss its financial and operational performance for the quarter and fiscal year ended March 31, 2026. The meeting, originally set for 4:30 PM IST, will now be held on May 27, 2026, at 5:30 PM IST. This adjustment provides investors and analysts a revised opportunity to hear directly from the company's leadership regarding the results for Q4 and FY26.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation serves as a formal update to the earlier communication dated May 20, 2026, ensuring all stakeholders are aligned with the new timing.

Key members of the management team will lead the discussion. The participants include Mr. Sameer Hiremath, Vice Chairman and Managing Director; Mr. Kuldeep Jain, Chief Financial Officer; Mr. Anish Swadi, Senior President, Business Transformation and Animal Health; and Mr. Manoj Mehrotra, President, Pharmaceuticals Business.

The conference call offers universal access for domestic and international investors. Participants can join via specific dial-in numbers provided for various regions, including Hong Kong, Singapore, the UK, and the USA. Strategic Growth Advisors Pvt. Ltd. is handling the RSVP coordination for the event.

Hikal Limited reported a consolidated net loss of ₹49 crore for the financial year ended March 31, 2026, compared to a net profit of ₹91 crore in the previous year. The annual loss was primarily driven by exceptional items totaling ₹85 crore, which included an impairment charge of ₹47 crore for repurposing a manufacturing plant at Panoli and costs related to new Labour Codes. For the quarter ended March 31, 2026, the company posted a net profit of ₹14 crore and revenue from operations of ₹519 crore. The board has recommended a total dividend of 30%, including a final dividend of 20%, subject to shareholder approval.

Q4 and FY26 Financial Performance

The quarterly performance showed a recovery, with EBITDA rising to ₹105 crore in Q4FY26 from ₹83 crore in the preceding quarter. However, annual profitability was impacted by the exceptional items. Excluding these items, the profit before tax (PBT) for the year stood at ₹7 crore. The company recorded a total revenue of ₹1,713 crore for FY26 and an EBITDA margin of 12.9%.

Operational Highlights

The Pharmaceutical business witnessed sequential improvement in EBIT margins, with H2 FY26 revenue growing 60% over H1 FY26 to ₹629 crore. The Crop Protection business accelerated during the quarter, with revenues growing 45% quarter-on-quarter and 13% year-on-year to ₹228 crore. Management indicated that the worst of the inventory correction cycle is behind them, though pricing challenges persist due to structural overcapacity and competition. The company also noted that its diversification strategy into Personal Care and Specialty Chemicals is gaining traction.

Outlook and Governance

Jai Hiremath, Executive Chairman, stated that the company is moving from a phase of remediation to sustainable growth. He highlighted that strategic investments in high-potency laboratories and pilot plants are now fully operational. The company expects new products in the Specialty Chemicals and Personal Care segments to contribute meaningfully from FY27 onwards. Additionally, the board appointed Mr. Sandip Parikh as an Additional Director in the category of Independent Director for a period of five years effective May 27, 2026.